This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Satsuma Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth €317.23K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Anahtar bilgiler
John Kollins
İcra Kurulu Başkanı
US$1.9m
Toplam tazminat
CEO maaş yüzdesi | 27.8% |
CEO görev süresi | 6.9yrs |
CEO sahipliği | 0.9% |
Yönetim ortalama görev süresi | 5.9yrs |
Yönetim Kurulu ortalama görev süresi | 5.8yrs |
Son yönetim güncellemeleri
Recent updates
CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Mar 31 2023 | n/a | n/a | -US$65m |
Dec 31 2022 | US$2m | US$530k | -US$70m |
Sep 30 2022 | n/a | n/a | -US$62m |
Jun 30 2022 | n/a | n/a | -US$61m |
Mar 31 2022 | n/a | n/a | -US$56m |
Dec 31 2021 | US$830k | US$500k | -US$51m |
Sep 30 2021 | n/a | n/a | -US$48m |
Jun 30 2021 | n/a | n/a | -US$47m |
Mar 31 2021 | n/a | n/a | -US$46m |
Dec 31 2020 | US$4m | US$456k | -US$48m |
Sep 30 2020 | n/a | n/a | -US$46m |
Jun 30 2020 | n/a | n/a | -US$42m |
Mar 31 2020 | n/a | n/a | -US$37m |
Dec 31 2019 | US$1m | US$391k | -US$28m |
Sep 30 2019 | n/a | n/a | -US$20m |
Jun 30 2019 | n/a | n/a | -US$13m |
Mar 31 2019 | n/a | n/a | -US$8m |
Dec 31 2018 | US$568k | US$362k | -US$7m |
Tazminat ve Piyasa: John's total compensation ($USD1.91M) is above average for companies of similar size in the German market ($USD407.72K).
Tazminat ve Kazançlar: John's compensation has increased whilst the company is unprofitable.
CEO
John Kollins (60 yo)
6.9yrs
Görev süresi
US$1,909,812
Tazminat
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% € 14.2k | |
VP & Head of Operations | 6.4yrs | Veri yok | Veri yok | |
Senior VP & Head of Chemistry | 5.9yrs | Veri yok | Veri yok | |
VP & Head of Regulatory Affairs | 5.1yrs | Veri yok | Veri yok |
5.9yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: 1LV's management team is seasoned and experienced (5.9 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
Independent Director | 2.9yrs | US$132.08k | 0% € 0 | |
Independent Director | 5.8yrs | US$131.58k | 0% € 0 | |
Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% € 0 | |
Independent Director | 6.5yrs | US$120.58k | 0% € 0 | |
Independent Director | 1.7yrs | US$124.58k | 0% € 0 | |
Independent Director | 7yrs | US$124.08k | 0% € 0 | |
Independent Director | 4.1yrs | US$132.08k | 0% € 0 | |
Independent Director | 5.7yrs | US$126.08k | 0% € 0 |
5.8yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 1LV's board of directors are considered experienced (5.8 years average tenure).